Endolysins as antimicrobials
- PMID: 22748813
- DOI: 10.1016/B978-0-12-394438-2.00007-4
Endolysins as antimicrobials
Abstract
Peptidoglycan (PG) is the major structural component of the bacterial cell wall. Bacteria have autolytic PG hydrolases that allow the cell to grow and divide. A well-studied group of PG hydrolase enzymes are the bacteriophage endolysins. Endolysins are PG-degrading proteins that allow the phage to escape from the bacterial cell during the phage lytic cycle. The endolysins, when purified and exposed to PG externally, can cause "lysis from without." Numerous publications have described how this phenomenon can be used therapeutically as an effective antimicrobial against certain pathogens. Endolysins have a characteristic modular structure, often with multiple lytic and/or cell wall-binding domains (CBDs). They degrade the PG with glycosidase, amidase, endopeptidase, or lytic transglycosylase activities and have been shown to be synergistic with fellow PG hydrolases or a range of other antimicrobials. Due to the coevolution of phage and host, it is thought they are much less likely to invoke resistance. Endolysin engineering has opened a range of new applications for these proteins from food safety to environmental decontamination to more effective antimicrobials that are believed refractory to resistance development. To put phage endolysin work in a broader context, this chapter includes relevant studies of other well-characterized PG hydrolase antimicrobials.
Copyright © 2012 Elsevier Inc. All rights reserved.
Similar articles
-
Bacteriophage virion-associated peptidoglycan hydrolases: potential new enzybiotics.Crit Rev Microbiol. 2013 Nov;39(4):427-34. doi: 10.3109/1040841X.2012.723675. Epub 2012 Sep 20. Crit Rev Microbiol. 2013. PMID: 22991936 Review.
-
Investigating novel Streptomyces bacteriophage endolysins as potential antimicrobial agents.Microbiol Spectr. 2025 Jan 7;13(1):e0117024. doi: 10.1128/spectrum.01170-24. Epub 2024 Nov 21. Microbiol Spectr. 2025. PMID: 39570052 Free PMC article.
-
Bacteriophage and peptidoglycan degrading enzymes with antimicrobial applications.Recent Pat Biotechnol. 2007;1(2):113-22. doi: 10.2174/187220807780809463. Recent Pat Biotechnol. 2007. PMID: 19075835 Review.
-
Taking aim on bacterial pathogens: from phage therapy to enzybiotics.Curr Opin Microbiol. 2007 Oct;10(5):461-72. doi: 10.1016/j.mib.2007.08.002. Epub 2007 Sep 27. Curr Opin Microbiol. 2007. PMID: 17904412 Review.
-
Bacteriophage endolysins as a novel class of antibacterial agents.Exp Biol Med (Maywood). 2006 Apr;231(4):366-77. doi: 10.1177/153537020623100402. Exp Biol Med (Maywood). 2006. PMID: 16565432 Review.
Cited by
-
Building blocks and blueprints for bacterial autolysins.PLoS Comput Biol. 2021 Apr 1;17(4):e1008889. doi: 10.1371/journal.pcbi.1008889. eCollection 2021 Apr. PLoS Comput Biol. 2021. PMID: 33793553 Free PMC article.
-
MEndoB, a chimeric lysin featuring a novel domain architecture and superior activity for the treatment of staphylococcal infections.mBio. 2024 Feb 14;15(2):e0254023. doi: 10.1128/mbio.02540-23. Epub 2024 Jan 26. mBio. 2024. PMID: 38275913 Free PMC article.
-
Enzybiotics: Enzyme-Based Antibacterials as Therapeutics.Adv Exp Med Biol. 2019;1148:233-253. doi: 10.1007/978-981-13-7709-9_11. Adv Exp Med Biol. 2019. PMID: 31482502 Review.
-
Direct Lytic Agents: Novel, Rapidly Acting Potential Antimicrobial Treatment Modalities for Systemic Use in the Era of Rising Antibiotic Resistance.Front Microbiol. 2022 Mar 3;13:841905. doi: 10.3389/fmicb.2022.841905. eCollection 2022. Front Microbiol. 2022. PMID: 35308352 Free PMC article. Review.
-
Two New M23 Peptidoglycan Hydrolases With Distinct Net Charge.Front Microbiol. 2021 Sep 24;12:719689. doi: 10.3389/fmicb.2021.719689. eCollection 2021. Front Microbiol. 2021. PMID: 34630350 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical